Nivolumab联合厄洛替尼治疗表皮生长因子受体突变(EGFR MT)的晚期NSCLC患者的安全性和缓解率

来源 :第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 | 被引量 : 0次 | 上传用户：aiming6946s

【摘要】

：

背景:厄洛替尼已获FDA批准用于表皮生长因子受体突变(EGFR MT)的非小细胞肺癌(NSCLC)一线治疗,中位无进展生存期(PFS)为10.4个月.Nivolumab是全人源化IgG4程序性死亡1(PD-1)免疫检查点抑制剂抗体,作为单药治疗晚期NSCLC患者显示了出令人鼓舞的安全性与生存获益.临床前数据支持EGFR路径活化PD-L1表达与免疫逃避在EGFR驱动的肺肿瘤中的作用.本摘要将报告评估

【作者】

：

Naiyer A.Rizvi Laura Q.Chow Hossein Borghaei Yun Shen Christopher Harbison Suresh Alaparthy Allen C.Chen Scott Gettinger

【机构】

：

Memorial Sloan-Kettering Cancer Center, New York, NY, USA

【出处】

：

第十七届全国临床肿瘤学大会暨2014年CSCO学术年会

【发表日期】

：

2014年11期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

其他文献

The immunoproteasome inhibitor PR-957 reactives latent HIV through P-TEFb

Although the current combined anti-retroviral therapy (cART) could successfully control HIV viraemia in infected patients under the detectable level, it fails to completely eradicate the pathogen.

会议

latent HIVPR-957Proteasome inhibitorP-TEFb

低剂量131I治疗低刺激性Tg、不伴有远处转移的高危分化型甲状腺癌

目的:目前尚无低剂量131I用于治疗低刺激性Tg、不伴有远处转移的高危分化型甲状腺癌的相关研究,本研究旨在探讨低剂量131I在这部分人群中的清甲效果.方法:纳入本回顾性研究的标准为:1)年龄＞18岁;2)分化型甲状腺癌全切术后;3)T4分期(术中肉眼可见甲外侵犯),任何N分期;4)清甲治疗前刺激性Tg≤5ng/ml;5)无远处转移的证据;6)TgAb≤46IU/ml.这部分患者在TSH刺激状态下(

会议

Safety and efficacy of the Asian subgroup of patients (pts) with EGFR-TKI-resistant advanced non-sma

Objective: AZD9291 is an oral, potent, irreversible EGFR-TKI, selective for sensitizing (EGFRm+) and T790M resistance mutations, currently under investigation in an ongoing Phase Ⅰ study of pts with E

会议

Dacomitinib versus Erlotinib in 2nd-/3rd-line NSCLC (ARCHER 1009 Global Phase Ⅲ trial):Outcomes in C

Objective: Dacomitinib (D) is an irreversible pan-HER kinase inhibitor.The ARCHER 1009 global phase Ⅲ study compared D and erlotinib (E) as treatment for locally advanced/metastatic non-small cell lun

会议

Tumorigenic potential of circulating tumor cells in pulmonary venous blood from Non-Small Cell Lung

Objective: To explore the clinical value and biological characteristics of circulating tumor cells (CTCs) in pulmonary vein (CTCs-pv) from patients with surgically resected non-small cell lung cancer

会议

Safety and clinical activity of pembrolizumab (pembro, MK-3475) in previously-treated patients (pts)

Objective:This Phase Ⅰ study evaluated the safety, tolerability, and clinical activity ofpembro, a selective anti-PD-1 antibody that blocks the interaction between programmed death-1 (PD-1) on T-cells

会议

Prophylactic cranial irradiation improved the overall survival of patients with surgically resected

Objective: We conducted a retrospective study to evaluate the role of prophylactic cranial irradiation (PCI) on patients with surgically resected small cell lung cancer(SCLC).Method: The records of co

会议

Pemetrexed continuation maintenance: An effective tolerable strategy for treating nonsquamous non-sm

Objective: A recent phase 3 study (PARAMOUNT) demonstrated that continuation maintenance therapy of pemetrexed is a new treatment paradigm for advanced nonsquamous NSCLC.The majority of patients enrol

会议

Testicular orphan receptor 4 (TR4) is a marker for metastasis and poor prognosis in NSCLC that drive

Objeetive: NSCLC are particularly aggressive tumors, with high invasive properties and metastatic potential.About 40％ stage Ⅰ and 60％ stage Ⅱ NSCLC patients are dying of distant metastases within 5 ye

会议

The Feasibility of EML4-ALK fusion gene, EGFR and K-ras mutations Detections by Malignant Pleural ef

Objective:To identify the feasibility of pleural effusion detection of epidermal growth factor receptor (EGFR) mutations, echinoderm microtubule-associated protein like 4 (EML4)-anaplastic lymphoma ki

会议

Nivolumab联合厄洛替尼治疗表皮生长因子受体突变(EGFR MT)的晚期NSCLC患者的安全性和缓解率

与本文相关的学术论文